In GBM mouse models, IDO1 expression in nonmalignant cells also promoted tumor progression, suggesting that the combined use of IDO1 inhibitors with radiotherapy and immunotherapy can improve treatment efficacy [119]. This evidence concerns the gene IDO1 and neoplasm.